



**Supplementary Figure 1. TNFR2<sup>+</sup> Tconvs express higher levels of Ki-67.** PBMCs from lung cancer patients were stained for CD4, CD25, CD127 and TNFR2 and then fixed and stained intracellularly for FoxP3 and Ki-67. FACS analysis was gated on FoxP3<sup>-</sup> Tconvs. Expression of Ki-67 by TNFR2<sup>+</sup> or TNFR2<sup>-</sup> Tconvs was further analyzed and compared. Typical FACS histograms are shown in the upper panel. The lower panel shows summary of Ki-67 expression by TNFR2<sup>+</sup> Tconvs and TNFR2<sup>-</sup> Tconvs (N=43).



**Supplementary Figure 2. Proportion of TNFR2<sup>+</sup> Tconvs is increased in the advanced cancer patients.** PBMCs were freshly isolated by Lymphoprep<sup>TM</sup> centrifugation and prepared for FACS analysis. FACS analysis was gated on FoxP3<sup>-</sup> Tconvs. Data shown is the comparison of TNFR2 expression by Tconvs derived from healthy controls (N=18), or stage I+II lung cancer patients (N=27), or stage III+IV lung cancer patients (N=16). *P* value shown in the figure is the comparison of indicated groups



**Supplementary Figure 3. In advanced cancer patients, Tregs express markedly higher levels of TNFR2 than Tconv.** PBMCs from advanced cancer patients (stage III+IV) were freshly isolated by Lymphoprep<sup>TM</sup> centrifugation and prepared for FACS analysis. The proportion of TNFR2-expressing cells and MFI of TNFR2 expression by Tregs and Tconv was analyzed and compared. *P* value shown in the figure is the comparison of indicated groups